Kasahara Toshihiko, Kuwayama Chitose, Hashiba Masamichi, Harada Tsuyoshi, Kakinuma Chihaya, Miyauchi Makoto, Degawa Masakuni
Department of Molecular Toxicology, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, Japan.
Cancer Sci. 2003 Jul;94(7):582-8. doi: 10.1111/j.1349-7006.2003.tb01486.x.
Altered gene expression of the DNA repair- and cell proliferation-associated proteins/enzymes was examined during the process of tamoxifen-induced hepatocarcinogenesis in female Sprague-Dawley rats. When rats were treated by gavage with a single dose of tamoxifen (20 mg/kg body weight) or with the same dose given at 24-h intervals for 2, 12 or 52 weeks, no histopathological change was observed in the liver after 2 weeks. Pathologically altered cell foci and placental form of glutathione-S-transferase (GST-P)-positive foci were observed in the liver after 12 weeks of treatment. Treatment for 52 weeks resulted in the formation of liver hyperplastic nodules that strongly expressed GST-P. During the process of carcinogenesis, changes in hepatic gene expression of DNA repair proteins/enzymes (XPA and XPC, xeroderma pigmentosum complementation groups A and C, respectively; APE, apurinic/apyrimidinic endonuclease) and of cell proliferation-associated proteins (c-myc; PCNA, proliferating cell nuclear antigen; cyclin D1, cyclin B, and p34cdc2) were examined by RT-PCR. The gene expression of XPA and APE was increased by the tamoxifen treatment for 2 or 12 weeks, but no increase was observed after the 52-week treatment. In addition, no significant change in XPC gene expression occurred at any period examined. The gene expression of c-myc, PCNA, and cyclin D1 was increased in a time-dependent fashion up to 12 weeks of treatment, and this increase was maintained up to 52 weeks of treatment. The gene expression of cyclin B and p34cdc2 was increased after the 1-day treatment, reverted to the control level at 2 and 12 weeks of treatment, and was remarkably increased after the 52-week treatment. In the present study, we demonstrate the altered gene expression of various proteins/enzymes involved in DNA repair, cell growth and the cell cycle during the process of tamoxifen-induced hepatocarcinogenesis. We discuss the relationship between the altered gene expression and hepatocarcinogenesis.
在雌性斯普拉格 - 道利大鼠的他莫昔芬诱导肝癌发生过程中,检测了与DNA修复及细胞增殖相关的蛋白质/酶的基因表达变化。当大鼠经口灌胃给予单剂量他莫昔芬(20 mg/kg体重)或每隔24小时给予相同剂量,持续2周、12周或52周时,2周后肝脏未观察到组织病理学变化。治疗12周后,肝脏中出现病理改变的细胞灶和谷胱甘肽 - S - 转移酶(GST - P)阳性的胎盘样病灶。治疗52周导致肝脏增生性结节形成,这些结节强烈表达GST - P。在致癌过程中,通过逆转录 - 聚合酶链反应(RT - PCR)检测了DNA修复蛋白/酶(分别为XPA和XPC,即着色性干皮病互补组A和C;APE,脱嘌呤/脱嘧啶内切酶)以及细胞增殖相关蛋白(c - myc;PCNA,增殖细胞核抗原;细胞周期蛋白D1、细胞周期蛋白B和p34cdc2)的肝脏基因表达变化。他莫昔芬治疗2周或12周后,XPA和APE的基因表达增加,但52周治疗后未观察到增加。此外,在任何检测时间段,XPC基因表达均无显著变化。c - myc、PCNA和细胞周期蛋白D1的基因表达在治疗至12周时呈时间依赖性增加,且这种增加持续至52周治疗。细胞周期蛋白B和p34cdc2的基因表达在治疗1天后增加,在治疗2周和12周时恢复至对照水平,在52周治疗后显著增加。在本研究中,我们证明了在他莫昔芬诱导肝癌发生过程中,参与DNA修复、细胞生长和细胞周期的各种蛋白质/酶的基因表达发生了改变。我们讨论了基因表达改变与肝癌发生之间的关系。